The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance

Annals of Oncology : Official Journal of the European Society for Medical Oncology
S SallahN P Nguyen

Abstract

Recent evidence indicates that patients with multiple myeloma receiving combination chemotherapy containing thalidomide are at a significantly high risk for venous thromboembolic disease (VTD). However, information on the occurrence of VTD in a related disorder, benign monoclonal gammopathy of undetermined significance (MGUS), is limited. We prospectively investigated patients with MGUS for the occurrence of VTD. The diagnosis of MGUS was based on well known criteria for the disorder. The variables examined were sex, age, race, presence of underlying conditions, level and type of immunoglobulin [serum monoclonal (M)-protein] platelet counts and level of fibrinogen. Of a total of 310 patients with MGUS, 19 (6.1%) developed VTD after a median follow-up of 44 months (range 12-67 months). In a univariate analysis, age >/=65 years (P=0.01), M-protein >/=16 g/l (P=0.001) and progression to plasma cell or lymphoproliferative disorders (28 of 310 patients; P=0.001) were significant risk factors for VTD. In multivariate analysis, M-spike >/=16 g/l [risk ratio (RR)=6.3; 95% confidence interval (CI) 2.25-17.6; P=0.001] and future development of plasma cell or lymphoproliferative disorder (RR = 4.2; 95% CI 1.64-10.7; P=0.003) were variable...Continue Reading

References

Mar 2, 1999·Archives of Pathology & Laboratory Medicine·D F KerenR H Tomar
Mar 2, 1999·Archives of Pathology & Laboratory Medicine·R A Kyle
Feb 22, 2002·The New England Journal of Medicine·Robert A KyleL Joseph Melton
Apr 11, 2002·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·M ZangariG Tricot

❮ Previous
Next ❯

Citations

Sep 10, 2011·Journal of Thrombosis and Thrombolysis·Yonal IpekSargin Deniz
Dec 21, 2007·Leukemia·A PalumboUNKNOWN International Myeloma Working Group
Nov 21, 2007·Hematology·Charles S Eby
Jun 19, 2013·Annals of Medicine·Jo CaersUNKNOWN Multiple Myeloma Study Group of the Belgian Hematological Society
Feb 3, 2016·La Revue de médecine interne·C de MoreuilA Delluc
Dec 27, 2011·Thrombosis Research·F Elice, F Rodeghiero
Jan 15, 2011·Seminars in Hematology·Sigurdur Yngvi KristinssonOla Landgren
Mar 17, 2009·Best Practice & Research. Clinical Haematology·Gregory C Connolly, Alok A Khorana
Aug 29, 2009·European Journal of Internal Medicine·Olivier DecauxBernard Grosbois
Sep 19, 2007·Clinical Lymphoma & Myeloma·Johannes J A AuwerdaFrank W G Leebeek
Nov 13, 2007·Hematology/oncology Clinics of North America·Robert A Kyle, S Vincent Rajkumar
Oct 16, 2015·Thrombosis Research·M ŠimkovičL Smolej
Aug 14, 2009·British Journal of Haematology·Jenny BirdUNKNOWN Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study
Feb 13, 2009·British Journal of Haematology·Charles Eby
Oct 15, 2010·European Journal of Haematology·Henrik GregersenHenrik T Sørensen
Dec 18, 2012·British Journal of Haematology·Tommaso ZaUNKNOWN Multiple Myeloma GIMEMA-Latium Region Working Group
May 29, 2010·British Journal of Haematology·James R BerensonRobert A Kyle
Apr 3, 2016·Disease-a-month : DM·Harry E FuentesJoseph A Caprini
Jul 16, 2014·Clinical Lymphoma, Myeloma & Leukemia·Riccardo ColomboRoberto Castelli
Jul 31, 2014·Thrombosis Research·Karl EganDermot Kenny
Oct 3, 2012·Thrombosis Research·Xavier Leleu
Apr 14, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Noppacharn UaprasertNigel S Key
Jan 14, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Maeve P CrowleyFionnuala Ní Áinle
Dec 12, 2012·Expert Review of Hematology·Eileen M BoyleXavier Leleu
Oct 19, 2017·Clinical Hemorheology and Microcirculation·G CaimiS Siragusa
Dec 17, 2014·Clinical Chemistry and Laboratory Medicine : CCLM·Massimo Franchini
Mar 7, 2007·Expert Review of Anticancer Therapy·Maurizio ZangariGuido Tricot
Sep 9, 2017·European Journal of Haematology·Charlene M McShaneLesley A Anderson
Feb 27, 2020·Case Reports in Rheumatology·Mateo Mejía-ZuluagaSebastián Herrera
Oct 13, 2020·Hematology Reports·Alessandra RomanoFrancesco Di Raimondo
Sep 19, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R BazM A Hussein

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.